Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
PURPOSE: Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal antibody (rhuMAb) HER2 has high affinity for p185HER2 and inhibits the growth of breast cancer cells that overexpress HER2. We evaluated the efficacy and toxicity of weekly intravenous administration of rhuMAb HER2 in patients with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: We treated 46 patients with metastatic breast carcinomas that overexpressed HER2. Patients received a loading dose of 250 mg of intravenous rhuMAb HER2, then 10 weekly doses of 100 mg each. Patients with no disease progression at the completion of this treatment period were offered a maintenance phase of 100 mg/wk. RESULTS: Study patients had extensive metastatic disease, and most had received extensive prior anticancer therapy. Adequate pharmacokinetic levels of rhuMAb HER2 were obtained in 90% of the patients. Toxicity was minimal and no antibodies against rhuMAb HER2 were detected in any patients. Objective responses were seen in five of 43 assessable patients, and included one complete remission and four partial remissions (overall response rate, 11.6%; 95% confidence interval, 4.36 to 25.9). Responses were observed in liver, mediastinum, lymph nodes, and chest wall lesions. Minor responses, seen in two patients, and stable disease, which occurred in 14 patients, lasted for a median of 5.1 months. CONCLUSION: rhuMAb HER2 is well tolerated and clinically active in patients with HER2-overexpressing metastatic breast cancers that had received extensive prior therapy. This is evidence that targeting growth factor receptors can cause regression of human cancer and justifies further evaluation of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,028
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Neu-Protein Overexpression in Breast Cancer
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811103191902 · Cited by 860
Cited by
Items 101–139 of 139
Rennert, P., Schneider, P., Cachero, T. G., Thompson, J., Trabach, L., Hertig, S., Holler, N., Qian, F., Mullen, C., Strauch, K., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.11.1677 · Cited by 252
Validation of Analytic Methods for Biomarkers Used in Drug Development
Chau, C. H., Rixe, O., McLeod, H., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4535 · Cited by 241
Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hösch, S., & Hayes, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2518 · Cited by 239
Arribas, J., & Borroto, A. (2002) · Chemical Reviews · doi:10.1021/cr010202t · Cited by 235
HER‐2/ neu Signal Transduction in Human Breast and Ovarian Cancer
Reese, D. M., & Slamon, D. J. (1997) · STEM CELLS · doi:10.1002/stem.150001 · Cited by 229
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229
Scott, A. M., Lee, F.-T., Tebbutt, N., Herbertson, R., Gill, S. S., Liu, Z., Skrinos, E., Murone, C., Saunder, T. H., Chappell, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611693104 · Cited by 222
Demystified …: Monoclonal antibodies
Nelson, P. N., Reynolds, G. M., Waldron, E. E., Ward, E., Giannopoulos, K., & Murray, P. G. (2000) · Molecular Pathology · doi:10.1136/mp.53.3.111 · Cited by 220
The role of EGF-related peptides in tumor growth
Normanno, N. (2001) · Frontiers in Bioscience · doi:10.2741/a635 · Cited by 216
ErbB-targeted therapeutic approaches in human cancer
Arteaga, C. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00104-0 · Cited by 215
Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies
Deo, Y. M., Graziano, R. F., Repp, R., & van de Winkel, J. G. J. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01007-4 · Cited by 213
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
Duffy, M. J., Mullooly, M., O'Donovan, N., Sukor, S., Crown, J., Pierce, A., & McGowan, P. M. (2011) · Clinical Proteomics · doi:10.1186/1559-0275-8-9 · Cited by 210
Lu, Y., Zi, X., & Pollak, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.11445 · Cited by 208
STAT signaling in the pathogenesis and treatment of leukemias
Lin, T. S., Mahajan, S., & Frank, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203486 · Cited by 205
Gilewski, T., Ragupathi, G., Bhuta, S., Williams, L. J., Musselli, C., Zhang, X.-F., Bencsath, K. P., Panageas, K. S., Chin, J., Hudis, C. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051626298 · Cited by 205
Self-citationMitra, D., Brumlik, M. J., Okamgba, S. U., Zhu, Y., Duplessis, T. T., Parvani, J. G., Lesko, S. M., Brogi, E., & Jones, F. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0295 · Cited by 204
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers
Thiel, K. W., Hernandez, L. I., Dassie, J. P., Thiel, W. H., Liu, X., Stockdale, K. R., Rothman, A. M., Hernandez, F. J., McNamara, J. O., & Giangrande, P. H. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks294 · Cited by 202
Petricevic, B., Laengle, J., Singer, J., Sachet, M., Fazekas, J., Steger, G., Bartsch, R., Jensen-Jarolim, E., & Bergmann, M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-307 · Cited by 192
“However, when administered as a monotherapy, this drug only yields response rates of 12% to 35% [10-12].”
Targeting the function of the HER2 oncogene in human cancer therapeutics
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210478 · Cited by 190
“…and it is now evident that trastuzumab induces tumor regression in approximately 30–35% of patients withHER2-amplified metastatic breast cancer if used as upfront therapy (Vogel et al., 2002; Mass et al., 2005), and has much less activity if used after other chemotherapies (Baselga et al., 1996).”
BackgroundFirst-Line Herceptin® Monotherapy in Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2001) · Oncology · doi:10.1159/000055400 · Cited by 190
“In addition, two phase II trials of Herceptin monotherapy [Baselga et al. 1996] and Herceptin in combination with cisplatin [Pegram et al. 1998] were undertaken.”
BackgroundSelf-citationIL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15950 · Cited by 180
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies
Goren, D., Horowitz, A., Zalipsky, S., Woodle, M., Yarden, Y., & Gabizon, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.625 · Cited by 179
Targeting ALK in neuroblastoma—preclinical and clinical advancements
Carpenter, E. L., & Mossé, Y. P. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.72 · Cited by 177
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
Tinoco, G., Warsch, S., Glück, S., Avancha, K., & Montero, A. J. (2013) · Journal of Cancer · doi:10.7150/jca.4925 · Cited by 176
The role of overexpressed HER2 in transformation
Neve, R. M., Lane, H. A., & Hynes, N. E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s9 · Cited by 173
“The recombinant human anti-HER2 monoclonal antibody, trastuzumab, has been effective in phase II and III clinical trials of women with HER2-positive metastatic breast cancer either as first-line therapy or in patients who had failed or relapsed after previous extensive treatment with chemotherapy [31-33].”
BackgroundEpidermal Growth Factor Receptor Family and Chemosensitization
Mendelsohn, J., & Fan, Z. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.5.341 · Cited by 171
Self-citationFixed Dosing of Monoclonal Antibodies in Oncology
Hendrikx, J. J. M. A., Haanen, J. B. A. G., Voest, E. E., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0167 · Cited by 168
Mackay, A., Jones, C., Dexter, T., Silva, R. L. A., Bulmer, K., Jones, A., Simpson, P., Harris, R. A., Jat, P. S., Neville, A. M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206349 · Cited by 163
“The ERBB2 receptor has become the first oncogene product to be targeted for breast cancer therapy, by the humanized anti-ERBB2 monoclonal antibody trastuzumab (Herceptin) (Baselga et al., 1996; Cobleigh et al., 1999; Slamon et al., 2001).”
BackgroundDisis, M. L., Knutson, K. L., Schiffman, K., Rinn, K., & McNeel, D. G. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006438507898 · Cited by 159
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 159
“In advanced breast cancers with HER2 overexpression, trastuzumab was shown to be active as a single agent in second-/third-line therapy (42, 43) and subsequently as first-line therapy (44).”
BackgroundLuo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1112 · Cited by 151
Xie, D., Miller, C. W., O'Kelly, J., Nakachi, K., Sakashita, A., Said, J. W., Gornbein, J., & Koeffler, H. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009755200 · Cited by 146
Mai, Z., Blackburn, G. L., & Zhou, J. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20300 · Cited by 111
“Suppression of HER2 receptor by using HER2 receptor inhibitor trastuzumab (herceptin) has been shown to significantly inhibit breast tumor growth in HER-2 overexpressing human breast cancer [7-9].”
BackgroundIL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production
Jaime-Ramirez, A. C., Mundy-Bosse, B. L., Kondadasula, S., Jones, N. B., Roda, J. M., Mani, A., Parihar, R., Karpa, V., Papenfuss, T. L., LaPerle, K. M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000328 · Cited by 100
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
Gill, K. L., Machavaram, K. K., Rose, R. H., & Chetty, M. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0361-4 · Cited by 82
Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., & Fujii, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0424 · Cited by 59
Therapeutic options for metastatic breast cancer
Morris, P. G., McArthur, H. L., & Hudis, C. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902834961 · Cited by 59
“Early studies with trastuzumab in MBC demonstrated response rates of between 12% and 15% in heavily pretreated patients [77,78] and up to 34% in the first-line setting [79].”
BackgroundSelf-citationHerceptin: From the Bench to the Clinic
Colomer, R., Shamon, L. A., Tsai, M. S., & Lupu, R. (2001) · Cancer Investigation · doi:10.1081/cnv-100000074 · Cited by 43
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215950 · Cited by 23
Metadata
- Authors
- Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., & Norton, L.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-03
- Volume
- 14
- Issue
- 3
- Pages
- 737-744
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2222638000
- Cited by
- 1,380
- References
- 28
- FWCI
- 26.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.